Which is more profitable, Bristol-Myers Squibb or McKesson?

Bristol-Myers Squibb keeps more of every sale as profit.

Which grows faster, Bristol-Myers Squibb or McKesson?

McKesson grew its sales faster in recent years.

Which is cheaper, Bristol-Myers Squibb or McKesson?

Bristol-Myers Squibb costs less for each unit of yearly profit (lower P/E).

Which has less debt, Bristol-Myers Squibb or McKesson?

McKesson would need fewer years of earnings to pay off its debt.

Bristol-Myers SquibbBMYvs

McKessonMCK

Bristol-Myers Squibb vs McKesson stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Bristol-Myers Squibb is more profitable and is cheaper for its profits. McKesson grows faster and has less debt.

Side by side

	Bristol-Myers Squibb	McKesson
	$130 billion	$127 billion
	14.6%	1.2%
	+2.5%	+11.1%
	18.4×	26.7×
	2.4 years	0.6 years
	13.9%	81.1%
	4.4%	0.4%

Open Bristol-Myers Squibb Open McKesson

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Bristol-Myers Squibb vs Medtronic · Bristol-Myers Squibb vs Novo Nordisk · Bristol-Myers Squibb vs Roche · Bristol-Myers Squibb vs Thermo Fisher Scientific · McKesson vs Cardinal Health · McKesson vs Cencora · McKesson vs Johnson & Johnson · McKesson vs Eli Lilly